|Day Low/High||111.33 / 113.82|
|52 Wk Low/High||101.36 / 132.13|
If you want a good read on the economy, look at the details of CSX's latest earnings report.
When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.
Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.
In this day and age, companies must be 'disruptors' or get left in the dust.
David Tepper's Appaloosa LP renews calls for changes at the top.
Eli Lilly shares traded lower Monday after it said it plans to launch a cut-price version of its top selling insulin treatment Humalog as pressure to lower drug costs continues to ripple through the pharmaceutical industry.
Jim Cramer lists the great stocks and the obvious winners he wishes he had talked about more.
If we can advance without China then who the heck knows where we can go with it.
Pets can bring significant profits to companies that cater to this niche market.
Today, a federal judge's opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic overpricing of insulin and concealment of a behind-the-scenes arrangement orchestrated to hike insulin...
As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.
Stocks ended lower Wednesday as investors found little in Donald Trump's State of the Union address to warrant extending recent market gains.
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Focus on individual stock picking, and take a look at small-caps, as earnings season continues.
U.S. stock futures mixed as investors remain worried the U.S. and China could fail to reach a trade agreement following Donald Trump's State of the Union address; Walt Disney rises as earnings beat estimates but expenses could rise from the company's new digital offerings; Snap soars as losses narrow and its user growth stabilizes.
The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
Jim Cramer makes sense of this market action and has your game plan for next week.
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.
The big week of corporate earnings is upon us.
Thursday's market action showed signs investors are moving away from safety plays, Jim Cramer says.
These themes are working despite the turmoil in Washington and slowing global growth.
Big pharma is shaping up to be a consolidating category in 2019.
Eli Lilly falls as a Phase 3 trial of drug for treatment of sarcoma didn't meet its primary endpoint.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lilly (Eli) & Co , where a total volume of 44,518 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 86.7% of LLY's average daily trading volume over the past month, of 5.1 million shares.
So far 2019 is proving to be a year where things have a habit of working out right.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
Left's firm Citron Research gives the $100+ stock a $35 price target.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.